Randomized multicentre pilot study of sacubitril/valsartan versus irbesartan in patients with chronic kidney disease: UK Heart and Renal Protection (UK HARP)-III. Rationale, trial design and baseline data
<p>Background: Patients with chronic kidney disease (CKD) are at risk of progression to end-stage renal disease and cardiovascular disease. Data from other populations and animal experiments suggest that neprilysin inhibition (which augments the natriuretic peptide system) may reduce these ri...
Main Authors: | Haynes, R, Judge, P |
---|---|
Format: | Journal article |
Published: |
Oxford University Press
2016
|
Similar Items
-
Effects of sacubitril/valsartan versus irbesartan in patients with chronic kidney disease: a randomised double-blind trial
by: Haynes, R, et al.
Published: (2018) -
Sacubitril/valsartan in peritoneal dialysis—lessons from a pharmacokinetic study
by: Judge, PK, et al.
Published: (2023) -
Sacubitril/valsartan for cardioprotection in breast cancer (MAINSTREAM): design and rationale of the randomized trial
by: Mateusz Tajstra, et al.
Published: (2023-10-01) -
Valsartan, Losartan and Irbesartan use in the USA, UK, Canada and Denmark after the nitrosamine recalls: a descriptive cohort study
by: Anton Pottegård, et al.
Published: (2023-04-01) -
Effects of Sacubitril/Valsartan on the Renal Resistance Index
by: Margherita Ilaria Gioia, et al.
Published: (2022-06-01)